See more : Generation Asia I Acquisition Limited (GAQ-WT) Income Statement Analysis – Financial Results
Complete financial analysis of Mural Oncology plc (MURA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mural Oncology plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KCM Holdings Corporation (KCMH) Income Statement Analysis – Financial Results
- Fast Retailing Co., Ltd. (9983.T) Income Statement Analysis – Financial Results
- ChenGuang Biotech Group Co., Ltd. (300138.SZ) Income Statement Analysis – Financial Results
- Francisco Industries, Inc. (FRAZ) Income Statement Analysis – Financial Results
- The Interpublic Group of Companies, Inc. (IPG) Income Statement Analysis – Financial Results
Mural Oncology plc (MURA)
About Mural Oncology plc
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.57M | 1.54M | 1.47M |
| Gross Profit | -2.57M | -1.54M | -1.47M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 162.03M | 170.07M | 159.82M |
| General & Administrative | 30.71M | 25.08M | 15.55M |
| Selling & Marketing | -667.00K | 0.00 | 0.00 |
| SG&A | 30.04M | 25.08M | 15.55M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 192.07M | 195.15M | 175.37M |
| Cost & Expenses | 194.64M | 195.15M | 175.37M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.57M | 1.54M | 1.47M |
| EBITDA | -192.72M | -183.38M | -173.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -194.64M | -195.15M | -175.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -649.00K | 10.22M | 0.00 |
| Income Before Tax | -195.29M | -195.15M | -175.37M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.16M | 4.88M | 68.00K |
| Net Income | -207.45M | -200.03M | -175.43M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -12.43 | -11.99 | -10.51 |
| EPS Diluted | -12.43 | -11.99 | -10.51 |
| Weighted Avg Shares Out | 16.69M | 16.69M | 16.69M |
| Weighted Avg Shares Out (Dil) | 16.69M | 16.69M | 16.69M |
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Nemvaleukin was generally well tolerated in ARTISTRY-1, a completed phase 1/2 clinical trial, with durable responses observed in both monotherapy and combination therapy across a range of heavily pretreated advanced solid tumors, including in platinum-resistant ovarian cancer (PROC), which does...
Mural Oncology to Participate in Two Upcoming Investor Conferences
WALTHAM, Mass. and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
WALTHAM, Mass and DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. and DUBLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today...
Source: https://incomestatements.info
Category: Stock Reports